Earnest Partners LLC Sells 18,815 Shares of Humana Inc. (NYSE:HUM)

Earnest Partners LLC lessened its stake in shares of Humana Inc. (NYSE:HUM) by 28.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,129 shares of the insurance provider’s stock after selling 18,815 shares during the period. Earnest Partners LLC’s holdings in Humana were worth $16,687,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in HUM. Aurora Investment Counsel raised its position in shares of Humana by 1.3% during the 4th quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after buying an additional 29 shares in the last quarter. Signaturefd LLC raised its position in shares of Humana by 1.2% during the 4th quarter. Signaturefd LLC now owns 2,634 shares of the insurance provider’s stock valued at $1,206,000 after buying an additional 30 shares in the last quarter. Brighton Jones LLC raised its position in shares of Humana by 6.8% during the 4th quarter. Brighton Jones LLC now owns 470 shares of the insurance provider’s stock valued at $215,000 after buying an additional 30 shares in the last quarter. Merit Financial Group LLC raised its position in shares of Humana by 2.1% during the 4th quarter. Merit Financial Group LLC now owns 1,770 shares of the insurance provider’s stock valued at $810,000 after buying an additional 37 shares in the last quarter. Finally, EP Wealth Advisors LLC raised its position in shares of Humana by 1.6% during the 4th quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock valued at $1,050,000 after buying an additional 37 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Jefferies Financial Group reduced their price objective on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research report on Monday, April 22nd. Oppenheimer reduced their price objective on shares of Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Truist Financial increased their price objective on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. TD Cowen increased their price objective on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, UBS Group reduced their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Fourteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $402.60.

Humana Stock Down 0.1 %

HUM traded down $0.51 during trading on Monday, hitting $392.12. The stock had a trading volume of 1,195,077 shares, compared to its average volume of 1,733,733. The company has a market capitalization of $47.25 billion, a PE ratio of 24.39, a PEG ratio of 2.27 and a beta of 0.51. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The stock has a 50 day simple moving average of $365.66 and a two-hundred day simple moving average of $347.02.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.